Speaker
Summary
The global adoption of targeted radionuclide diagnostics & therapies continues to accelerate, driving unprecedented demand for reliable, high‑quality medical radioisotopes. ITM has established a unique and resilient production and supply infrastructure for therapeutic radioisotopes with a proven track record in supplying n.c.a. Lutetium‑177 for clinical and commercial applications worldwide. ITM identified and covers four foundational pillars to a reliable and scalable supply of medical radioisotopes: secured access to raw materials, a robust and diversified irradiation network, established and expanding GMP production capacity, and strong global sales and logistics capabilities.
Looking ahead, ITM is applying these same principles to Actinium‑225, a therapeutic alpha emitter with growing clinical and industry interest. To translate the previous success to the production of Actinium-225, ITM has founded the joint venture Actineer, together with Canadian Nuclear Laboratories (CNL). With the cyclotron-based Ra-226 (p, 2n) Ac-225 reaction a closed-loop production strategy with proven feasibility is being applied. By combining technological innovation, supply‑chain integration, and strategic partnerships, Actineer aims to unlock the long‑term capacity needed to support continuous global ramp‑up and meet future clinical and commercial demand for Actinium-225.
| Are you interested/eligible for the Young Session? | No, I am not eligible |
|---|
